|
Miltefosine
| Gastroinstestinal disorders | Vomiting, diarrhoea | Anorexia, nausea | Abdominal pain, thrombocytopenia |
| Hepatobiliary disorders | Increased activity of liver enzymes | | |
| Renal and urinary disorders | | Increased blood urea nitrogen, creatinine | |
| Immune disorders | | | Steven–Johnson syndrome |
|
Paromomycin
| Skin | | Pruritus | |
| Gastrointestinal disorders | | Nausea, metallic taste | Vomiting |
| General | Headache, lethargy, mild injection-site pain | Pyrexia, reversible abnormal audiogram | Injection site swelling, abscess, ototoxicity, conductive deafness, proteinuria |
| Hepatobiliary disorders | | Transient increases in alanine and aspartate transaminases | Increased alkaline phosphatase, blood bilirubin |
|
Liposomal amphotericin B
| Skin | | Pruritus | |
| General and infusion related | Chills/rigor, fever, nausea, vomiting, hypertension, tachycardia, breathlessness, hypoxia, rash, anaemia, insomnia, malaise, fatigue, confusion, muscle weakness or cramps | Chest tightness, chest pain, breathlessness, difficulty in breathing (possibly with wheeze), flushing, vasodilation lowering blood pressure, musculoskeletal pain (described as joint pain, back pain or bone pain), stomach pain, headache, bleeding into skin, unusual bruising and prolonged bleeding after injury, fits or seizures, pain and swelling around the infusion site | Heart attack, severe swelling around lip, eyes or tongue, muscle breakdown, bone and joint pain |
| Hepatobiliary disorders | Increased alkaline phosphatase | | |
| Gastrointestinal disorders | Diarrhoea, nausea, vomiting | | |
| Blood disorders | High blood sugar, low potassium, low magnesium, low calcium, low sodium | | Anaemia with symptoms of excessive fatigue and breathlessness after light activity, a pale complexion, interference in blood phosphorus test results |
| Renal and urinarydisorders | Increased blood urea nitrogen, increased creatinine | | Kidney failure |
|
Amphotericin B deoxycholate
| General and infusion related | Fever (sometimes accompanied by shaking chills, usually within 15–20 min of initiation of treatment), malaise, weight loss, hypotension, tachypnoea, pain at the injection site with or without phlebitis or thrombophlebitis, generalized pain, including muscle and joint pains | Flushing, anaphylactoid and other allergic reactions, bronchospasm, wheezing, rash, in particular maculopapular, pruritus | |
| Cardiopulmonary | | Cardiac arrest, shock, cardiac failure, pulmonary oedema, hypersensitivity pneumonitis, arrhythmia, including ventricular fibrillation, dyspnoea, hypertension | |
| Hepatobiliary disorders | | | |
| Gastrointestinal disorders | Anorexia, nausea, vomiting, diarrhoea, dyspepsia, cramping, epigastric pain | Acute liver failure, hepatitis, jaundice, haemorrhagic gastroenteritis, melena | |
| Blood disorders | Normochromic, normocytic anaemia | Agranulocytosis, coagulation defects, thrombocytopenia, leukopenia, eosinophilia, leukocytosis | |
| Renal and urinary disorders | Decreased renal function and renal function abnormalities, including azotaemia, hypokalaemia, hyposthenuria, renal tubular acidosis and nephrocalcinosis. Usually improves with interruption of therapy but some permanent impairment, especially in patients receiving large amounts (> 5 g) of amphotericin B or other nephrotoxic agents | Acute renal failure, anuria, oliguria | |
| Neurological symptoms | | Convulsions, hearing loss, tinnitus, transient vertigo, visual impairment, diplopia, peripheral neuropathy, encephalopathy, other neurological symptoms | |
|
Sodium stibogluconate
| General and infusion related | Flushing, sweating, fever, rash, yellow skin and eyes, pain and thrombosis on intravenous administration, pain at injection site if given intramuscularly, abdominal pain, anorexia, malaise, myalgia, arthralgia, headache and lethargy | | Anaphylaxis, rigor, exacerbation of lesions on the cheek, substernal pain |
| Cardiopulmonary | Fatal cardiac arrhythmia, changes in electrocardiogram, including reduction in T-wave amplitude, T-wave inversion and QT prolongation, transient coughing | Pneumonia | |
| Hepatobiliary disorders | Transient rise in serum lipase and amylase, symptomatic pancreatitis | | |
| Gastrointestinal disorders | Bleeding from nose or gums | | |
| Blood disorders | | | Transient reductions in platelets, white blood cells and haemoglobin |
| Neurological symptoms | Vertigo | | |
|
Meglumine antimoniate
| General and infusion related | Headache, general malaise, difficulty in breathing, skin rash, facial oedema. Precautions to be taken before systemic administration: a protein-rich diet throughout treatment, correction of iron-deficiency anaemia or specific deficiencies to be corrected before treatment. Cardiac, hepatic and renal functions must be monitored throughout the treatment (instructions from product package insert) | | |
| Cardiopulmonary | Cardiac changes (dose dependent and generally reversible): T-wave insertion and QT interval prolongation | | Cardiac arrhythmia |
| Gastrointestinal disorders | Abdominal pain, increased liver enzyme activity | | Pancreatitis |
| Renal and urinary disorders | | | Acute renal insufficiency |
|
Pentamidine
| General | Local pain at injection site, induration, sterile abscess, nausea, vomiting, abdominal pain, hypotension, syncope, hypoglycaemia, diabetes mellitus | | |
| Blood and lymphatic system | | Leukopenia, thrombocytopenia, anaemia | |
| Metabolism and nutrition | Azotaemia | Hypoglycaemia, hyperglycaemia, hyperkalaemia, hypocalcaemia, hypomagnesaemia | |
| Nervous system | | Syncope, dizziness | |
| Vascular | | Hypotension, flushing | |
| Cardiopulmonary | | | QT interval prolongation, cardiac arrhythmia |
| Gastrointestinal | | Nausea, vomiting, taste disturbance | Pancreatitis (rare) |
| Hepatobiliary | | Abnormal liver function | |
| Skin and subcutaneous tissue | | Rash | Stevens-Johnson syndrome (frequency unknown) |
| Renal and urinary | Acute renal failure, macroscopic haematuria | | |
